Phase 1, Open-label, Randomized, Parallel Study to Assess the Pharmacokinetic Comparability of 2 Formulations and to Evaluate Pharmacokinetic Comparability of Guselkumab (CNTO1959) Delivered by 2 Different Devices in Healthy Subjects
Latest Information Update: 29 Jan 2020
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Crohn's disease; Erythrodermic psoriasis; Familial adenomatous polyposis; Hidradenitis suppurativa; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 05 Jun 2013 New trial record
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.